Regeneron Pharmaceuticals Inc. buy Rothschild & Co Redburn
Start price
14.08.25
/
50%
€481.00
Target price
14.08.26
€759.88
Performance (%)
36.49%
Price
14:18
€653.80
Summary
This prediction is currently active. With a performance of 36.49% the BUY prediction by Rothschild___Co_Redb is a big success. Dividends of €2.70 are taken into consideration when calculating the performance. This prediction currently runs until 14.08.26. The prediction end date can be changed by Rothschild___Co_Redb at any time. Rothschild___Co_Redb has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Regeneron Pharmaceuticals Inc. | 3.538% | 3.538% |
| iShares Core DAX® | -0.201% | 5.471% |
| iShares Nasdaq 100 | 2.573% | 10.092% |
| iShares Nikkei 225® | 0.598% | 9.871% |
| iShares S&P 500 | 1.804% | 7.404% |
Comments by Rothschild___Co_Redb for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is now covered by analysts at Rothschild & Co Redburn. They set a "buy" rating and a $890.00 price target on the stock.
Ratings data for REGN provided by MarketBeat